0001601830-24-000127.txt : 20240819 0001601830-24-000127.hdr.sgml : 20240819 20240819190942 ACCESSION NUMBER: 0001601830-24-000127 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240815 FILED AS OF DATE: 20240819 DATE AS OF CHANGE: 20240819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mauro David J CENTRAL INDEX KEY: 0001621172 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 241222229 MAIL ADDRESS: STREET 1: 36 TERRELL DRIVE CITY: WASHINGTON CROSS STATE: PA ZIP: 18977 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 wk-form4_1724108977.xml FORM 4 X0508 4 2024-08-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001621172 Mauro David J 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Medical Officer 0 Class A Common Stock 2024-08-15 4 F 0 14146 6.69 D 229616 D Stock Option (Right to Buy) 10.09 2034-02-09 Class A Common Stock 0 99537 D Stock Option (Right to Buy) 8.77 2033-06-01 Class A Common Stock 0 381426 D Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date. /s/Jonathan Golightly, attorney-in-fact 2024-08-19